Revolution Medicines Inc
$ 80.52
-0.28%
29 Dec - close price
- Market Cap 15,610,575,000 USD
- Current Price $ 80.52
- High / Low $ 80.92 / 79.80
- Stock P/E N/A
- Book Value 8.42
- EPS -5.19
- Next Earning Report 2026-03-02
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.32 %
- ROE -0.61 %
- 52 Week High 81.97
- 52 Week Low 29.17
About
Revolution Medicines, Inc. is an innovative clinical-stage oncology company headquartered in Redwood City, California, dedicated to advancing transformative therapies for RAS-addicted cancers. By harnessing the principles of precision medicine, the company focuses on targeting previously "undruggable" cancer drivers, addressing critical unmet medical needs within the oncology landscape. With a robust pipeline of cutting-edge treatments and strategic collaborations with industry leaders, Revolution Medicines is poised to significantly improve patient outcomes, presenting a compelling investment opportunity for institutional investors seeking exposure to next-generation cancer therapeutics.
Analyst Target Price
$83.26
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-06 | 2025-05-06 | 2025-02-24 | 2024-11-06 | 2024-08-07 | 2024-05-08 | 2024-02-26 | 2023-11-06 | 2023-08-08 | 2023-05-08 | 2023-02-27 |
| Reported EPS | -1.61 | -1.31 | -1.13 | -1.12 | -0.94 | -0.81 | -0.7 | -1.14 | -0.99 | -0.92 | -0.72 | -0.63 |
| Estimated EPS | -1.41 | -1.12 | -0.75 | -0.9645 | -0.89 | -0.77 | -0.75 | -0.88 | -1.01 | -0.82 | -0.81 | -0.82 |
| Surprise | -0.2 | -0.19 | -0.38 | -0.1555 | -0.05 | -0.04 | 0.05 | -0.26 | 0.02 | -0.1 | 0.09 | 0.19 |
| Surprise Percentage | -14.1844% | -16.9643% | -50.6667% | -16.1223% | -5.618% | -5.1948% | 6.6667% | -29.5455% | 1.9802% | -12.1951% | 11.1111% | 23.1707% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-02 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -1.54 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RVMD
2025-12-28 12:09:27
Harbor Capital Advisors Inc. significantly reduced its stake in Revolution Medicines (NASDAQ:RVMD) by 63% in Q3 2025, now holding approximately $1.01 million worth of shares. Despite this, other institutional investors have increased their positions, and company insiders have also been selling shares. Analysts generally maintain a "Buy" rating with a consensus target price of $78.50, even though the company missed its latest EPS estimate.
2025-12-24 16:09:42
Revolution Medicines, Inc. has announced the advancement of daraxonrasib (RMC-6236) into a Phase 3 trial named “RASolute 304” for pancreatic ductal adenocarcinoma (PDAC) patients. This trial aims to assess if adding the targeted oral drug after surgery and chemotherapy can reduce cancer recurrence compared to standard observation. This development signifies a strengthened late-stage pipeline for the company and could position daraxonrasib as a differentiated treatment in a challenging market segment, providing long-term upside potential, though near-term revenue impacts are not expected.
2025-12-23 09:09:40
Revolution Medicines Inc. (RVMD) reached an all-time high of $81.49, with a current market capitalization of $15.74 billion, reflecting strong investor confidence and a remarkable 84.36% increase over the past year. Analysts maintain a "Strong Buy" recommendation with a target of $104, despite the company not being profitable over the last twelve months and appearing overvalued by some estimates. The surge is attributed to innovative developments and strategic advancements in its pipeline, including investments in potential breakthrough cancer treatments, as highlighted by a recent earnings report showing increased R&D costs and a larger net loss.
2025-12-22 17:08:42
Revolution Medicines Inc. stock reached an all-time high of $81.49, with a current market capitalization of $15.74 billion and a strong "Strong Buy" consensus from analysts. Despite not being profitable over the last year, the company has seen significant stock increases, driven by innovative developments and upcoming clinical trial results. InvestingPro offers further insights into the company's financial data and future potential.
2025-12-22 03:09:37
Revolution Medicines has advanced its RAS(ON) multi-selective inhibitor, daraxonrasib, into a Phase 3 trial for resectable pancreatic ductal adenocarcinoma, expanding its clinical footprint in difficult-to-treat cancers. This move reinforces the company's focus on mutation-driven tumors, adding another potential value driver. While this is a significant step, short-term catalysts remain focused on readouts from ongoing Phase 3 programs and regulatory interactions, with financing and execution risks still present due to forecasted net losses.
2025-12-21 03:09:33
Revolution Medicines has randomized its first patient in the pivotal RASolute 304 Phase 3 trial for pancreatic cancer, boosting its stock by 80.94% over 90 days and 257.44% over three years. Despite a high price-to-book ratio of 9.5x, suggesting overvaluation compared to the broader biotech industry, the market is placing significant emphasis on the future success of its RAS(ON) inhibitor pipeline. Investors are paying a premium for the company's potential in cutting-edge oncology, with its valuation appearing more modest against a narrower peer group.
